Home > News > Recent cases

SkyKick UK Ltd v Sky Ltd [2024] UKSC 3613 November 2024Adrian Speck KC appeared for the successful Appellants (“SkyKick”) in the proceedings issued by the Respondents (“Sky”) alleging infringement of several SKY marks, and passing off, by SkyKick’s use of SKYKICK for email migration and cloud storage services. In this landmark decision, the Supreme Court held that the registration of a trade mark can be […]
Kieran Corrigan v Timol [2024] EWCA Civ 123318 October 2024Jonathan Hill appeared for the Appellant, Kieran Corrigan & Co Limited (“KCL”) in its appeal against the decision of Jonathan Hilliard KC (sitting as a Deputy High Court Judge) (“the Judge”) to dismiss claims for breach of confidence against the Respondent (“Mr. Timol”). The claims related to the alleged misuse by a company of which […]
Sandoz AG v Biogen MA Inc [2024] EWHC 2567 (Pat)11 October 2024Michael Tappin KC appeared for the Claimants (Sandoz) and Justin Turner KC appeared for the Defendant (Biogen). Sandoz sought revocation of Biogen’s patent and an Arrow declaration, while Biogen counterclaimed for infringement. Biogen’s patent in suit, EP 967, related to a method for assessing the risk of progressive multifocal leukoencephalopathy (PML) in multiple sclerosis (MS) […]
BioNTech SE v CureVac SE [2024] EWHC 2538 (Pat)8 October 2024Michael Tappin KC and Michael Conway appeared for the successful Claimant (BioNTech) in this action seeking revocation of two of the Defendant’s (CureVac) patents. The patents, EP 668 and EP 755 were divisionals from a common earlier application and their descriptions were materially identical. They claimed artificial mRNA molecules in which the poly(A) tail was […]
Accord Healthcare v Regents of the University of California [2024] EWHC 2524 (Pat)8 October 2024Justin Turner KC appeared for the Claimants and Andrew Lykiardopoulos KC appeared for the Defendants in this action to revoke the patent and invalidate the SPC owned by the First Defendant and exclusively licensed to the Second Defendant. The patent in suit, EP 196, claimed the compound enzalutamide for the treatment of hormone refractory prostate […]